Crinetics Pharmaceuticals IncCRNX
Price$84.95

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $42.2M+3,957.4% YoYTTM through 30 Jun 2026
Net Income -$501.6MTTM through 30 Jun 2026
Free Cash Flow -$425.2MTTM through 30 Jun 2026

Margins

Current
Gross Margin98.1%
Operating Margin-1,307.5%
Net Margin-1,189.9%

Returns

-42.1%ROE
-37.9%ROA

Balance Sheet Health

Debt / Equity0.04x
Current Ratio18.24x
Net Debt-$1.2Bnet cash position
Cash & Equivalents$55.5M

Quality Metrics

Altman Z-Score39.58
Piotroski F-Score2 / 9
FCF Margin-1,008.6%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $7.7M
Diluted EPS-$5.05TTM
'20'21'22'23'24'25
FY2025: $-4.95

Dividend

No dividend

Capital Allocation

Capex Intensity6.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.